Tom Pickles, S. Larry Goldenberg, Gary Steinhoff

Canadian Journal of Urology, Vol.12, No.3, pp. 2684-2686, 2005

Abstract This article has no abstract. More >

Howard H. Pai^1,2, Francis Lau²

Canadian Journal of Urology, Vol.12, No.3, pp. 2700-2709, 2005

Abstract Introduction: Providing men with prostate cancer (MPC) timely access to their health records and information (HRI) can enhance their ability to understand their condition and engage in shared medical decision making with their health care provider (HCP). The Internet is a potential means of enhancing such interactions.
Materials and methods: Two surveys were conducted at a PC support group in Victoria, BC to identify the health information needs of MPC and the ability to access their HRI. Another objective was to identify the potential role of web-enabled HRI systems at meeting these needs. Sixty-one participants (41 men… More >

Uzair B. Chaudhary¹, Mohammad H. Rashid¹, Adedayo A. Onitilo², Nabil K. Bissada³

Canadian Journal of Urology, Vol.12, No.3, pp. 2666-2676, 2005

Abstract Prostate cancer is a heterogeneous disease and clinical outcomes vary considerably after failure of primary androgen ablation. With the development of new therapeutics the management of patients with androgen independent prostate cancer has changed considerably over the last few years. Multiple secondary hormonal manipulations are available and may lead to prolonged periods of clinical response. These maneuvers include the use of oral antiandrogens, antiandrogen withdrawal, ketoconazole, aminoglutethimide, corticosteroids and use of estrogenic compounds. This article reviews the clinical activity of these agents in management of patients with advanced prostate cancer. More >

Ross E. Gray¹, Richard J. Wassersug², Christina Sinding³, Angela M. Barbara¹, Christine Trosztmer¹, Neil Fleshner⁴

Canadian Journal of Urology, Vol.12, No.4, pp. 2755-2763, 2005

Abstract Objective: This exploratory study was intended to investigate men's ways of integrating and understanding experiences with Androgen Deprivation Therapy (ADT), including how hormone treatment affected their sense of identity.
Patients and methods: Twelve men, averaging 61 years of age and treated with ADT, participated in a single interview about their experiences with prostate cancer and hormone treatment. In keeping with a qualitative approach, questions were initially open-ended, with patients encouraged to describe experiences in their own words.
Results: Seven prominent themes appeared in the interviews: 1) starting on hormones, 2) matching expectations with reality, 3) tracking changes, 4)… More >

Wigdan Al-Sukhni, Ami Grunbaum, Neil Fleshner

Canadian Journal of Urology, Vol.12, No.5, pp. 2841-2842, 2005

Abstract Essiac is a popular complementary and alternative medicine (CAM) that is utilized by many cancer patients in North America. Much anecdotal reporting exists about its cancer-fighting qualities, but so far no clinical trials have been preformed to validate those claims. We describe here the case of a 64-year-old man whose hormone-refractory prostate cancer responded well to Essiac tea. More >

Anna R. Gagliardi¹, Neil Fleshner², Bernard Langer³, Hartley Stern³, Adalsteinn D. Brown⁴

Canadian Journal of Urology, Vol.12, No.5, pp. 2808-2815, 2005

Abstract Objectives: There is evidence of variation in both the processes and outcomes of prostate cancer care, resulting in possible harm to patients and increased costs to the health system. Care could be improved by first identifying critical, measurable indicators that correlate with quality of care. This work was conducted to develop indicators of prostate cancer care using a modified three-step Delphi approach.
Methods: A 17-member multidisciplinary panel reviewed potential indicators extracted from the medical literature through two consecutive rounds of rating followed by consensus discussion. The panel then prioritized the indicators selected in the previous two rounds.
Results:… More >

Canadian Journal of Urology, Vol.12, No.6, pp. 2873-2879, 2005

Abstract Background: Assessment of prostate cancer (PCa) specific and generic health-related quality-of-life (HRQOL) is frequently omitted due to several obstacles, such as respondent burden and infrastructure-related limitations. We attempted to reduce the number of items of two commonly used HRQOL assessment tools, namely the UCLA PCa Index (PCI) and the RAND SF-12, with the intent of generating the most parsimonious, yet psychometrically valid and reliable HRQOL assessment tool.
Methods: The PCI and SF-12 were administered to 2415 radical prostatectomy patients, and re-tested in a convenience sample of 35 men with PCa. Multivariate linear regression models defined the most… More >

Cheng Dong^1,2,3, Margaret J. Slattery^2,3, Shile Liang³, Hsin-Hsin Peng²

Molecular & Cellular Biomechanics, Vol.2, No.3, pp. 145-160, 2005, DOI:10.3970/mcb.2005.002.145

Abstract Attachment of tumor cells to the endothelium (EC) under flow conditions is critical for the migration of tumor cells out of the vascular system to establish metastases. Innate immune system processes can potentially promote tumor progression through inflammation dependant mechanisms.\nobreakspace {} White blood cells, neutrophils (PMN) in particular, are being studied to better understand how the host immune system affects cancer cell adhesion and subsequent migration and metastasis. Melanoma cell interaction with the EC is distinct from PMN-EC adhesion in the circulation. We found PMN increased melanoma cell extravasation, which involved initial PMN tethering on… More >

Anna Maria Witkowska¹, Maria Halina Borawska²

European Cytokine Network, Vol.15, No.2, pp. 91-98, 2004

Abstract Soluble intercellular adhesion molecule-1 (sICAM-1) represents a circulating form of ICAM-1 that is constitutively expressed or is inducible on the cell surface of different cell lines. It serves as a counter-receptor for the lymphocyte function-associated antigen (LFA-1). Interaction between ICAM-1, present on endothelial cells, and LFA-1 facilitates leukocyte adhesion and migration across the endothelium. ICAM-1 and its circulating form have been implicated in the development of any number of diseases. More >

Satoru Iwase, Tadashi Murakami, Yuichiro Saito, Keiichi Nakagawa

European Cytokine Network, Vol.15, No.4, pp. 312-316, 2004

Abstract Changes in blood cytokines of 28, consenting, terminally ill cancer patients were studied to determine a relationship between cachexia and changes in cytokine levels. Levels of PTHrP and five types of cytokines considered to be associated with cachexia, TNFα, IL-1β, IL-6, IFNγ and LIF, were measured during routine blood examination and were compared with clinical findings. With the exception of TNF-α, which was detected in one patient, only IL-6 was detected in all 28 patients recruited in this study. Ten patients showed a sharp elevation of IL-6 just before death, following a 40-day period in… More >